Should methotrexate remain the first-line drug for psoriasis?

Affiliations

¹ Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, ON M5T 2S8, Canada. Electronic address: dafna.gladman@utoronto.ca.

Comment

Dafna D Gladman. Lancet. 2017.

. 2017 Feb 4;389(10068):482-483.

doi: 10.1016/S0140-6736(16)32574-0. Epub 2016 Dec 22.

¹ Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, ON M5T 2S8, Canada. Electronic address: dafna.gladman@utoronto.ca.

No abstract available

Comment on

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, Zschocke I, Falk TM, Blödorn-Schlicht N, Reich K. Warren RB, et al. Lancet. 2017 Feb 4;389(10068):528-537. doi: 10.1016/S0140-6736(16)32127-4. Epub 2016 Dec 22. Lancet. 2017. PMID: 28012564 Clinical Trial.